News

Kristen Stewart to Join BD as Senior Vice President of Strategy and Investor Relations

  • BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Kristen Stewart to the newly created position of senior vice president of Strategy and Investor Relations.
    08/17/2020

BD to Present at UBS Genomics 2.0 and MedTech Innovations Virtual Summit

  • BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the UBS Genomics 2.0 and MedTech Innovations Virtual Summit on Thursday, August 13, 2020, at 3:30 p.m. ET.
    08/13/2020
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Becton, Dickinson and Company (BDXB) can buy. Click on Rating Page for detail.

The price of Becton, Dickinson and Company (BDXB) is 48.16 and it was updated on 2024-07-27 07:02:20.

Currently Becton, Dickinson and Company (BDXB) is in undervalued.

News
    
News

BD and BD Foundation commit $7.8 million to helping community health centers expand innovative care to patients

  • BD (NYSE: BDX), a leading global medical technology company, together with the BD Foundation, its charitable affiliate, today committed $7.8 million in monetary grants and product donations over the next three years to support the continued expansion of the BD Helping Build Healthy Communities™ initiative – a unique public-private partnership launched in 2013 and implemented jointly by Direct Relief and the National Association of Community Health Centers (NACHC).
    Mon, Aug. 10, 2020

Calculating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

  • Today we will run through one way of estimating the intrinsic value of Becton, Dickinson and Company (NYSE:BDX) by...
    Mon, Aug. 10, 2020

Becton Dickinson Earnings Top, But BDX Stock Falls On Weak Sales

  • Becton Dickinson earnings beat views, but the coronavirus test maker missed on revenue and gave weak full-year guidance below expectations. Shares tumbled out of a buy zone early Thursday,
    Thu, Aug. 06, 2020

US STOCKS-Wall Street gains as markets look to aid package, Nasdaq closes above 11,000

  • Shares on Wall Street shrugged off a sluggish start and closed higher on Thursday, with the Nasdaq ending the session above 11,000 for the first time as investors hoped for a new fiscal stimulus package. The tech-heavy Nasdaq clinched a new record high in early trading, and closed above the 11,000-mark for the first time after initially climbing above it on Wednesday. The benchmark S&P 500 and blue-chip Dow were about 1% and 7% away from their own peaks scaled in February.
    Thu, Aug. 06, 2020

US STOCKS-Wall Street gains as markets await aid package, U.S. jobs data

  • Shares on Wall Street rose on Thursday but moved within narrow ranges, as investors awaited a new fiscal stimulus package to bolster the country's economy and digested better-than-expected U.S. jobless claims data. The tech-heavy Nasdaq clinched a new record high in early trading, crossing the 11,000-mark for a second straight day but has yet to close above the threshold. The benchmark S&P 500 and blue-chip Dow were about 2% and 8% away from their own peaks scaled in February.
    Thu, Aug. 06, 2020
SEC Filings
SEC Filings
More Headlines
News

US STOCKS-S&P 500 flat as Congress wrangles over stimulus

  • The S&P 500 treaded water on Thursday as investors awaited a new fiscal aid package to prop up the economy, with data showing a staggering 31.3 million Americans were receiving unemployment checks in mid-July. The tech-heavy Nasdaq clinched a new record high in early trading. The benchmark S&P 500 and blue-chip Dow were about 2% and 8% away from their own peaks scaled in February.
  • 08/06/2020

Becton, Dickinson's Debt Overview

  • Over the past three months, shares of Becton, Dickinson Inc. (NYSE: BDX) fell by 1.87%. Before having a look at the importance of debt, let's look at how much debt Becton, Dickinson has.Becton, Dickinson's Debt Based on Becton, Dickinson's balance sheet as of May 7, 2020, long-term debt is at $16.81 billion and current debt is at $4.36 billion, amounting to $21.17 billion in total debt. Adjusted for $2.35 billion in cash-equivalents, the company's net debt is at $18.82 billion.To understand the degree of financial leverage a company has, shareholders look at the debt ratio. Considering Becton, Dickinson's $53.52 billion in total assets, the debt-ratio is at 0.4. Generally speaking, a debt-ratio more than 1 means that a large portion of debt is funded by assets. As the debt-ratio increases, so the does the risk of defaulting on loans, if interest rates were to increase. Different industries have different thresholds of tolerance for debt-ratios. For example, a debt ratio of 40% might be higher for one industry, whereas normal for another.Importance of Debt Debt is an important factor in the capital structure of a company, and can help it attain growth. Debt usually has a relatively lower financing cost than equity, which makes it an attractive option for executives.However, interest-payment obligations can have an adverse impact on the cash-flow of the company. Having financial leverage also allows companies to use additional capital for business operations, allowing equity owners to retain excess profit, generated by the debt capital.See more from Benzinga * Insider Sells Becton, Dickinson's Stock * Benzinga's Top Upgrades, Downgrades For July 9, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
  • 08/06/2020

US STOCKS-Wall St struggles for direction as Congress wrangles over stimulus

  • The benchmark S&P 500 and blue-chip Dow were about 2% and 8% away from their own peaks scaled in February. Economic data released on Thursday painted a mixed picture as Labor Department numbers showed a first fall in jobless claims in three weeks, while a separate report showed a 54% surge in job cuts announced by employers in July. "The (stocks) treading water might be waiting for tomorrow's actual number... The other most important thing that's going on is the stimulus bill, and the lack of agreement between the White House and the Democratic party as to what the deal ought to include," said Tom Martin, senior portfolio manager at GLOBALT Investments in Atlanta.
  • 08/06/2020

Becton Dickinson on track to produce 1 bln syringes in 12-18 months

  • 08/06/2020

Becton Dickinson (BDX) Earnings Surpass Estimates in Q3

  • Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.
  • 08/06/2020

Becton Dickinson (BDX) Q3 Earnings Beat Estimates

  • Becton Dickinson (BDX) delivered earnings and revenue surprises of 7.32% and -1.88%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
  • 08/06/2020

Colliers International Reports Second Quarter Results

  • Investment Management, Outsourcing & Advisory demonstrate resilience, diversificationOperating highlights:   Three months ended Six months ended   June 30 June 30 (in millions of US$, except EPS)2020 2019 2020 2019               Revenues$550.2  $745.5 $1,180.8  $1,380.6 Adjusted EBITDA (note 1) 60.0   87.3  114.4   130.9 Adjusted EPS (note 2) 0.70   1.10  1.25   1.61               GAAP operating earnings 14.5   57.2  33.1   70.6 GAAP EPS (0.26)  0.60  (0.14)  0.63 TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI) today announced operating and financial results for the quarter ended June 30, 2020, which were significantly impacted by the global COVID-19 pandemic. All amounts are in US dollars.For the second quarter ended June 30, 2020, revenues were $550.2 million, down 26% (25% in local currency) relative to the same quarter in the prior year, adjusted EBITDA (note 1) was $60.0 million, down 31% (30% in local currency) and adjusted EPS (note 2) was $0.70, down 36% versus the prior year period. Second quarter adjusted EPS would have been approximately $0.02 higher excluding foreign exchange impacts. GAAP operating earnings were $14.5 million, relative to $57.2 million in the prior year quarter. GAAP EPS was a loss of $0.26 per share, relative to $0.60 per share in the prior year quarter. Second quarter GAAP EPS would have been approximately $0.02 higher excluding changes in foreign exchange rates.For the six months ended June 30, 2020, revenues were $1.18 billion, down 14% (13% in local currency) relative to the same period in the prior year, adjusted EBITDA (note 1) was $114.4 million, down 13% (11% in local currency) and adjusted EPS (note 2) was $1.25, down 22% versus the prior year period. Year-to-date adjusted EPS would have been approximately $0.04 higher excluding foreign exchange impacts. GAAP operating earnings were $33.1 million, relative to $70.6 million in the prior year period. GAAP EPS for the six month period was a loss of $0.14 per share, relative to $0.63 per share in the prior year period. Second quarter GAAP EPS would have been approximately $0.04 higher excluding changes in foreign exchange rates.“Colliers reported better than expected results across all segments and regions during the second quarter despite the unprecedented impact of COVID-19, especially in Leasing and Capital Markets. Fortunately, the majority of our earnings now come from Investment Management and Outsourcing & Advisory – high value-add professional services that are recurring and contractual – providing us with more resilience and service line diversification than ever,” said Jay S. Hennick, Global Chairman and CEO of Colliers International. “Pandemic uncertainty in Leasing and Capital Markets continue to impact our results, though we expect gradual improvement for the balance of the year. During the quarter, we completed a $230 million offering of convertible notes to fortify our balance sheet and completed the acquisitions of Dougherty, a US commercial real estate debt finance, loan servicing and securities platform (now rebranded as Colliers Mortgage) and Maser Consulting, a leading US engineering design and service firm focused on real estate assets and related infrastructure. With a highly diversified and balanced global business, strong balance sheet, entrepreneurial culture, and significant insider ownership, we are confident that Colliers will emerge from this crisis stronger than ever,” he concluded.About Colliers International Group Inc. Colliers International (NASDAQ, TSX: CIGI) is a leading real estate professional services and investment management company. With operations in 68 countries, our more than 15,000 enterprising professionals work collaboratively to provide expert advice to maximize the value of property for real estate occupiers, owners and investors. For more than 25 years, our experienced leadership, owning approximately 40% of our equity, has delivered compound annual investment returns of almost 20% for shareholders. In 2019, corporate revenues were more than $3.0 billion ($3.5 billion including affiliates), with $33 billion of assets under management in our investment management segment.Learn more about how we accelerate success at corporate.colliers.com, Twitter @Colliers or LinkedIn.Consolidated Revenues by Line of Service With the closing of Colliers Mortgage acquisition, Colliers has renamed its Sales Brokerage service line to Capital Markets, which now includes sales brokerage, mortgage origination and mortgage investment banking revenues. In addition, the Company added mortgage loan servicing under its Outsourcing & Advisory revenues.  Three months ended   Six months ended   (in thousands of US$) June 30ChangeChange June 30ChangeChange (LC = local currency) 2020 2019in US$ %in LC% 2020 2019in US$ %in LC%                   Outsourcing & Advisory $257,044 $281,638-9%-6% $534,334 $540,022-1%1% Investment Management  41,389  46,902-12%-12%  87,214  89,992-3%-3% Leasing  136,768  253,374-46%-45%  301,278  435,158-31%-30% Capital Markets  115,005  163,603-30%-28%  258,008  315,468-18%-17% Total revenues $550,206 $745,517-26%-25% $1,180,834 $1,380,640-14%-13% Consolidated revenues for the second quarter declined 25% on a local currency basis, driven primarily by expected declines in transactional Leasing and Capital Markets activity due to the COVID-19 pandemic. Consolidated internal revenues measured in local currencies were down 26% (note 3).For the six months ended June 30, 2020, consolidated revenues declined 13% on a local currency basis, with the impact of the pandemic beginning in March 2020. Consolidated internal revenues measured in local currencies were down 15% (note 3).Segmented Quarterly Results Revenues in the Americas region totalled $308.9 million for the second quarter compared to $421.4 million in the prior year quarter, down 27% (26% in local currency) on reduced Leasing and Capital Markets activity across the region. Outsourcing & Advisory revenues were flat in the quarter. Adjusted EBITDA was $24.4 million, versus $36.2 million in the prior year quarter. GAAP operating earnings were $3.4 million, relative to $25.6 million in the prior year quarter.Revenues in the EMEA region totalled $99.6 million for the second quarter compared to $151.6 million in the prior year quarter, down 34% (32% in local currency) on lower activity in each service line, including Outsourcing & Advisory which was impacted by delays in executing on-site turnkey project management assignments due to the pandemic. Adjusted EBITDA was $6.3 million, versus $19.0 million in the prior year. GAAP operating earnings were a loss of $3.3 million as compared to $10.8 million in the second quarter of 2019.Revenues in the Asia Pacific region totalled $100.1 million for the second quarter compared to $125.1 million in the prior year quarter, down 20% (16% in local currency) on lower Leasing and Capital Markets activity. Outsourcing & Advisory revenues were up slightly in the quarter, including incremental revenues from the recent Synergy acquisition, now rebranded as Colliers Project Leaders. Adjusted EBITDA was $12.3 million, down from $14.2 million. GAAP operating earnings were $5.1 million, down from $12.5 million in the prior year quarter.Investment Management revenues for the second quarter were $41.4 million compared to $46.9 million in the prior year quarter, down 12% (12% in local currency). The second quarter revenue decline was primarily attributable to a $4.3 million reduction in pass-through revenue from legacy carried interest versus the prior year quarter. Adjusted EBITDA was $17.4 million relative to $19.2 million in the prior year quarter, attributable to the timing of certain European transaction fees, which were elevated in the prior year quarter. GAAP operating earnings were $10.6 million in the quarter, versus $12.2 million in the prior year quarter. Assets under management were $35.7 billion at June 30, 2020, up 2% from $35.1 billion at March 31, 2020 and up 18% from $30.3 billion at June 30, 2019.Unallocated global corporate costs as reported in Adjusted EBITDA were $0.3 million in the second quarter, relative to $1.3 million in the prior year quarter, and were favourably impacted by lower insurance costs and lower variable expenses. The corporate GAAP operating loss for the quarter was $1.4 million, relative to $4.1 million in the second quarter of 2019.Impact of COVID-19 Pandemic The full impact of the pandemic continues to remain uncertain. The Company is updating the working assumption previously provided to reflect: (i) better than anticipated results for the second quarter across all service lines and regions; and (ii) the recently completed acquisitions of Colliers Mortgage and Maser Consulting. The updated working assumption for the full year 2020 (relative to 2019), is as follows: PreviousUpdatedAdd acquisitionsUpdated with acquisitions Revenue-15% to -25%-15% to -25%+5%-10% to -20% Adjusted EBITDA-25% to -35%-20% to -30%+5%-15% to -25% This working assumption is based on the best available information and is subject to change based on numerous macroeconomic, health, social, political and related factors.Transactional Leasing and Capital Markets revenues are expected to remain below 2019 levels, although the scale of decline should moderate in the third and fourth quarters. Investment Management and Outsourcing & Advisory are expected to remain relatively stable for the balance of the year with some variability depending on market conditions.The Company has taken significant steps to adjust costs to expected revenues across all service lines, including reductions to support, administrative and leadership and related costs.
  • 08/06/2020

Becton Dickinson profit slumps nearly 37% on delayed surgeries

  • 08/06/2020

BD Announces Results For 2020 Third Fiscal Quarter; Provides Fiscal 2020 Guidance

  • BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.855 billion for the third fiscal quarter ended June 30, 2020. This represents a decrease of 11.4 percent as reported from the prior-year period, or 9.4 percent on a currency-neutral basis.
  • 08/06/2020

Why Becton, Dickinson (BDX) Might Surprise This Earnings Season

  • Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
  • 08/05/2020

What's in Store for Becton, Dickinson's (BDX) Q3 Earnings?

  • Becton, Dickinson's (BDX) fiscal third-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.
  • 08/04/2020

BD releases FY 2019 Sustainability Report

  • BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2019 Sustainability Report, focusing on performance of the environmental, social and governance factors that support the company's 2020 Sustainability Goals from October 1, 2018 to September 30, 2019 (FY 2019).
  • 08/03/2020

Becton, Dickinson Receiving $24 Million Federal Investment to Ramp Up Coronavirus Test Kit Manufacturing

  • Becton, Dickinson (NYSE: BDX) is about to increase production of its SARS-CoV-2 diagnostic solution thanks to the largesse of two arms of the federal government. The healthcare equipment specialist announced Thursday that the Department of Defense (DOD), supported by the Department of Health and Human Services (HHS), is providing it with a $24 million investment for the purpose. The money will be devoted to the production of Becton, Dickinson's Veritor System for Rapid Detection of SARS-CoV-2, a test that the company says can produce results within 15 minutes of being administered.
  • 07/31/2020

BD Announces $24 Million U.S. Government Investment to Support Scale Up of U.S. Manufacturing of COVID-19 Diagnosic Tests

  • BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $24 million investment from the U.S. Department of Defense in collaboration with the U.S. Department of Health and Human Services to support the scale up of U.S. manufacturing capabilities for BD Veritor™ Solution for Rapid Detection of SARS-CoV-2 (see demo here).
  • 07/30/2020

Cross-Sector: Market Data Highlights

  • 07/30/2020

Why Becton, Dickinson & Co (BDX) is an Attractive Pick for Investors

  • Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Equity Income Fund posted a return of 18.29% for the quarter, underperforming its benchmark, the S&P; 500 Index which returned 20.55% in the same quarter. You should check out Brown Advisory’s top 5 stock picks for investors […]
  • 07/17/2020

2 Top Pharma Stocks to Buy in a Recession

  • When the economy struggles, these two pharma companies take it in stride because they know the rest of the industry depends on them for critical products.
  • 07/17/2020

T Rowe Price Equity Income Fund's Top 5 Buys in the 2nd Quarter

  • Fund of Baltimore-based firm establishes new holdings in Merck and Volkswagen Continue reading...
  • 07/16/2020

Colliers International Group Inc. Announces Normal Course Issuer Bid

  • TORONTO, July 16, 2020 -- Colliers International Group Inc. (NASDAQ: CIGI) (TSX: CIGI) (“Colliers”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted a.
  • 07/16/2020

U.S. government agrees to buy Becton's COVID-19 testing devices

  • The U.S. Department of Health and Human Services has agreed to buy 2,000 of its BD Veritor Plus Systems and 750,000 of its SARS-CoV-2 antigen test kits, the company said. According to U.S. health experts, broad testing for the virus in the country needs to be ramped up as the White House considers when and how to lift stay-at-home restrictions and lockdowns triggered by the pandemic. "There is absolutely a recognized need for this type of testing," Dave Hickey, president of Becton Dickinson's integrated diagnostic solutions business, said in an interview.
  • 07/16/2020

Becton Dickinson Covid Test Systems Bought by U.S. Government

  • Becton Dickinson's system will 'significantly expand testing ... for the benefit of all Americans,' the government said.
  • 07/15/2020

Becton, Dickinson Score Fed Contract For Covid-19 Rapid Test Systems

  • Becton, Dickinson and Co (BDX) has announced that the U.S. Department of Health and Human Services (HHS) will purchase 2,000 of its BD Veritor Plus Systems and 750,000 SARS-CoV-2 antigen test kits for Covid-19 detection.“The BD Veritor Plus System for rapid detection of SARS-CoV-2 is the latest point-of-care testing advance that will significantly expand testing in distributed locations for the benefit of all Americans,” said Admiral Brett P. Giroir, assistant secretary for Health and COVID-19 testing coordinator. “This development will help identify community spread of the virus by further enabling rapid diagnosis of COVID-19.”BD began shipping limited quantities of its BD Veritor Plus SARS-CoV-2 antigen test kits to distributors last week as it ramps up production capacity. BD is leveraging its global manufacturing network and scale and expects to increase capacity to be able to produce 2 million tests per week by the end of September. The company expects to produce up to 10 million tests from July through September.Earlier this month, the U.S. Food and Drug Administration (FDA) granted BD an Emergency Use Authorization (EUA) for the system. Clinical studies performed at more than 20 sites across the U.S. demonstrated that the test is capable of achieving 84% sensitivity and 100% specificity, which is in line with the performance from similar immunoassay tests.Similar to all immunoassay tests, FDA recommends that negative test results be confirmed by a molecular method to confirm the result, if necessary, for patient management.Shares in BDX are currently trading down 3% year-to-date, and analysts have a cautiously optimistic take on the stock’s outlook with a Moderate Buy consensus. Meanwhile the average analyst price target of $276 indicates 5% upside potential lies ahead. (See BDX stock analysis on TipRanks).Wells Fargo analyst Larry Biegelson recently reiterated his buy rating on the stock, citing the Covid-19 antigen tests. If BDX managed to sell 2 million tests/ week at an average price of $18, this would generate a further $470 million in revenue per quarter, calculates Biegelson. As this is not yet included in his model, it represents potential upside to estimates going forward, the analyst noted.Related News: Boston Scientific Mulls Billion-Dollar Snake Venom Sale- Report Abbott Labs, Edwards Lifesciences Settle Heart Device Patent Disputes Akebia Initiates Vadadustat Study In Covid-19 Patients More recent articles from Smarter Analyst: * Google Snaps Up 7.7% Stake In India’s Jio Platform For $4.5B * Apple Wins $15 Billion European Court Ruling On Irish Taxes * UnitedHealth Reports Earnings Beat With Strong Optum Performance * Sony Increasing Production On PlayStation 5 By 50%- Report
  • 07/15/2020

U.S. government agrees to buy Becton's COVID-19 testing device

  • Becton, Dickinson and Co said on Wednesday the U.S. government had agreed to buy its COVID-19 testing device and kits. The U.S. Department of Health and Human Services has agreed to buy its 2,000 BD Veritor Plus Systems and 750,000 SARS-CoV-2 antigen test kits, the company said. Becton said distribution for the device and kits is set to begin from next week.
  • 07/15/2020

BD to sell 750,000 coronavirus tests to U.S. government

  • Becton Dickinson and Co. said Wednesday that the U.S. government plans to buy 750,000 of the company's COVID-19 antigen diagnostic tests. The purchase will also include 2,000 systems manufactured by BD to run the tests. BD was granted an emergency use authorization from the Food and Drug Administration for the rapid, point-of-care test earlier this month, making it the third of its diagnostics tests to receive emergency authorization. The regulator, also in July,issued an alert about the risk of false-positive results for another one of BD's diagnostic coronavirus tests. BD's stock is down 3.1% year-to-date, while the S&P; 500 has declined 1.0%.
  • 07/15/2020

BD Supports U.S. Government Efforts to Increase COVID-19 Testing Capacity with Point-of-Care Tests

  • BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today a commitment from the U.S. Department of Health and Human Services (HHS) to purchase BD diagnostic solutions in expanding access to rapid point-of-care testing for COVID-19 through a broad, decentralized network of testing instrumentation.
  • 07/15/2020

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

  • Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
  • 07/14/2020

Colliers International Group Inc. to Announce Second Quarter Results on August 6, 2020

  • TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI), announced today that results for the second quarter ended June 30th, 2020 will be issued by press release on Thursday August 6th, 2020 at approximately 7:00am ET. The conference call to review these financial results will take place at 11:00am ET on Thursday August 6th, 2020 and will be hosted by Jay S. Hennick, Chairman & CEO, John Friedrichsen, COO and Christian Mayer, CFO. The numbers to use for this call are: 1) toll-free 1-877-402-8911; or 2) for international callers 1-707-927-4894, with the conference ID number 1587213 for all participants.The conference call will also be accessible on our website at Corporate.Colliers.com in the “Events” section. For anyone unable to listen to the scheduled call, the rebroadcast number will be 1-855-859-2056 with conference ID 1587213.  The rebroadcast and archive recording of the conference call will be available at the above noted web address for 90 days following the call.About Colliers International Group Colliers International (NASDAQ, TSX: CIGI) is a leading real estate professional services and investment management company. With operations in 68 countries, our more than 15,000 enterprising professionals work collaboratively to provide expert advice to maximize the value of property for real estate occupiers, owners and investors. For more than 25 years, our experienced leadership, owning approximately 40% of our equity, has delivered compound annual investment returns of almost 20% for shareholders. In 2019, corporate revenues were more than $3.0 billion ($3.5 billion including affiliates), with $33 billion of assets under management in our investment management segment. Learn more about how we accelerate success at corporate.colliers.com, Twitter@Colliers or LinkedIn.For further information, please contact: Christian Mayer, CFO Colliers International Group Inc. (416) 960-9500
  • 07/14/2020

Insider Sells Becton, Dickinson's Stock

  • Becton, Dickinson Inc (NYSE:BDX) was trading 1.6% higher from the previous closing price. A Form 4 filing filed with the SEC on Monday, July 13 showed that EVP & Pres Life Sciences Kaltenbach Patrick sold 1,272 shares at an average price of $260.00. The transaction moved the executive's stake in Becton, Dickinson Inc. to 10,340 shares.Why Insider Transactions Are Important? While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their company can be a good added factor that leads to more conviction in a decision.When an insider buys stock after an important sell off, that can indicate the insider's faith in the success of the organization. Henceforth, if the stock is bought at new highs, it might be because the insider feels that the stock is not overvalued. Insiders who sell stock at new lows could be anticipating some capitulation moment. If the insider sells at new highs, it could point to the intention to "take some profit" and "lock in a gain."Transaction Codes To Focus On Wall Street tends to focus on insider transactions which take place in the open market, viewed inside a Form 4 filing via codes P for purchase and S for sale. If the transaction was an open-market transaction, that means that the insider made a concious decision for the company's stock moving forward.Transaction codes other than P or S are often viewed with less conviction as they are often not tied to a decision by the exec. As an example, transaction code C indicates the conversion of an option. Transaction code A indicates the insider may have been forced to sell shares in order to receive compensation the exec was promised upon being hired by a company.See more from Benzinga * Benzinga's Top Upgrades, Downgrades For July 9, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
  • 07/13/2020

Colliers International Completes Acquisition of Maser Consulting

  • TORONTO and RED BANK, N.J., July 13, 2020 -- Leading global commercial real estate services and investment management firm, Colliers International (NASDAQ and TSX: CIGI), has.
  • 07/13/2020

Becton Dickinson Forms $70M Covid-19 Partnership With U.S. For Syringes

  • Becton Dickinson (BDX) has formed a $70 million public-private partnership with the U.S. government for the manufacturing of injection devices used for COVID-19 vaccines.As part of the partnership, the U.S. Biomedical Advanced Research and Development Authority (BARDA) will invest an estimated $42 million into a $70 million capital project to further expand BD's operations and production capacity in Nebraska, where it has manufactured medical devices for nearly 70 years.The new capacity, which is expected to be online within 12 months, will grant BARDA priority access to injection devices from the new manufacturing lines to meet mass vaccination needs for COVID-19 and future pandemics.The medical technology company said it finalized an initial order for 50 million needles and syringes to be delivered by the end of December this year for the U.S. government’s COVID-19 vaccination needs. The company added that it continues to work closely with the U.S. government for additional quantities of injection devices under the Operation Warp Speed vaccine program, which seeks to begin supplying millions of doses of a safe, effective vaccine for COVID-19 in 2021."BD's commitment to produce 50 million vaccine injection devices by the end of this year to support the U.S. COVID-19 vaccination campaign is the latest effort in the company's multifaceted global response to this virus," said Rick Byrd, BD’s Medication Delivery Solutions president. "Over the past four years, BD has committed to invest more than $340 million in our Nebraska facilities."BD does not expect the order to have an impact on its ability to meet existing customer requirements for needles and syringes, including the annual flu vaccination and childhood immunization campaigns.The world’s largest manufacturer of injection devices said that in addition to the U.S., it has also received orders from other countries, including Canada and the U.K.The U.S. government order comes as BD earlier this week announced that the U.S. Food and Drug Administration granted emergency-use authorization (EUA) for its portable COVID-19 antigen test that delivers results in 15 minutes.BD will ramp-up manufacturing capacity to 2 million tests per week by the end of September and seeks to produce up to 10 million tests from July through September.Five-star analyst Larry Biegelsen at Wells Fargo, who reiterated a Buy rating on the stock, said that assuming 2 million tests per week would be produced at an average price of $18, the COVID-19 antigen test could generate revenue of about $470 million per quarter, if BD would sell all of its capacity.Shares rose 1.2% to $254.49 in early afternoon trading. The stock is still down 7.6% so far this year and analysts have a cautiously optimistic Moderate Buy consensus on the stock with 6 Buy ratings versus 7 Hold ratings. The $273 average price target indicates 7.7% upside potential in the shares over the coming 12 months. (See BDX stock analysis on TipRanks).Related News: Novavax Spikes 42% Pre-Market On $1.6B U.S. Funding For Covid-19 Candidate Corvus Shoots Up 115% On Start Of Novel Immunotherapy Study In Covid-19 Patients GenMark Soaring In Pre-Market On 118% Revenue Explosion More recent articles from Smarter Analyst: * Moderna Completes Enrollment For Phase 2 Covid-19 Vaccine Study * KKR To Snap Up Global Atlantic For Foothold In Insurance Industry * National General Pops 69% In Pre-Market On $4B Takeover Deal By Allstate * AstraZeneca-Merck Pancreatic Cancer Drug Wins European Approval
  • 07/08/2020

U.S. govt to invest $42 mln in Becton Dickinson's injection device production

  • Becton Dickinson and Co said on Wednesday the U.S. government will invest $42 million to expand the medical technology company's manufacturing lines for injection devices to support vaccination efforts against COVID-19. The investment is under a public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office, Becton Dickinson said. BARDA has invested more than $3 billion in vaccines and funded more than 30 projects as part of "Operation Warp Speed," the White House program aimed at accelerating access to vaccines and treatments for the new coronavirus.
  • 07/08/2020

BD to get $42 million to manufacture vaccine injection devices

  • Becton Dickinson & Co. said Wednesday that it will receive $42 million from the U.S. government to build out manufacturing capacity for vaccine injection devices, to be used during the coronavirus pandemic. The Biomedical Advanced Research and Development Authority awarded the funding as part of Operation Warp Speed, a Trump administration program aimed at having 300 million doses of a COVID-19 vaccine in January. BD, which says it is the largest manufacturer of injection devices in the world, said the total cost of the capital project is $70 million. BD's stock is down 7.5% since the start of the year, while the S&P; 500 has declined 2.6%.
  • 07/08/2020

BD Partners with U.S. Government on $70 Million Manufacturing Infrastructure Project for Mass Vaccination Campaigns

  • BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to develop new manufacturing lines for injection devices that will provide priority access to the U.S. government for hundreds of millions of syringes and needles to support current and future pandemic vaccination efforts.
  • 07/08/2020

Is Colliers International Group Inc (CIGI) A Good Stock To Buy?

  • We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
  • 07/08/2020

Were Hedge Funds Right About Piling Into Becton, Dickinson and Company (BDX)?

  • The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
  • 07/07/2020

Becton Dickinson Virus Test Prompts FDA False-Positive Alert

  • The FDA issued an alert for one of Becton Dickinson's coronavirus tests due to an increased risk of false-positive results.
  • 07/07/2020

FDA alerts health care providers about false positives for one of BD's COVID-19 tests

  • Shares of Becton Dickinson & Co. were down 0.7% in premarket trading on Tuesday, the day after the Food and Drug Administration issued an alert about an increased risk of false-positive results for one of BD's COVID-19 diagnostic tests. In one study, 3% of the results were false positive for the BD Max System test, which received an emergency use authorization from the regulator in April. "Consider any positive result presumptive from tests using the BD SARS-CoV-2 Reagents for the BD Max System," the FDA said. "Consider confirming with an alternate authorized test." A spokesperson confirmed that BD had received reports of the false-positive results, saying that "the elevated rates represent a small subset of the positive results" and that the company is in discussions with the FDA about the issue. On Monday, BD had announced the launch of a point-of-care COVID-19 antigen test that can detect the coronavirus in 15 minutes, the third of its COVID-19 diagnostic test. BD's stock is down 7.9% since the start of the year. The S&P; 500 has declined 1.5% year-to-date.
  • 07/07/2020

BD Launches First and Only Fully Sterile Povidone-Iodine and Isopropyl Alcohol Skin Preparation

  • BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of BD PurPrep™ patient preoperative skin preparation with sterile solution, the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation (PVP-I; 0.83% available iodine and 72.5% isopropyl alcohol) commercially available in the United States.
  • 07/07/2020

FDA Authorizes Becton, Dickinson Portable 15-Minute Coronavirus Test

  • Healthcare technology specialist Becton, Dickinson (NYSE: BDX) announced Monday that it has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for an antigen test that can effectively detect the presence of the coronavirus. According to Becton, Dickinson, it is also very fast; the company says it can produce results in 15 minutes. At the moment, according to Becton, Dickinson, the BD Veritor Plus System is in use in over 25,000 healthcare facilities within the U.S. It is used to test for illnesses such as flu.
  • 07/06/2020

U.S. FDA alerts on false positive result from Becton Dickinson COVID-19 test

  • The U.S. Food and Drug Administration alerted clinical laboratories and healthcare providers on Monday about false positive results from one of Becton Dickinson and Co's COVID-19 molecular diagnostic tests. The test, designed to detect viral nucleic acid from the virus that causes COVID-19, is in use in nearly every state across the U.S. at hundreds of laboratories. In one study, the manufacturer found about 3% of the results were false positives, according to the FDA.
  • 07/06/2020

Covid Report: Medical Giant Surges On Its 15-Minute Coronavirus Test

  • Becton Dickinson gained U.S. authorization for its third coronavirus test on Monday, sending BDX stock higher at the close. Gilead Sciences and Mylan also gained remdesivir nods.
  • 07/06/2020

Miami Mayor Shuts Down Restaurants Except for Takeout and Delivery

  • • Miami is closing restaurants for both indoor and outdoor dining again, along with “ballrooms, banquet facilities, party venues, gyms and fitness centers, and short-term rentals,” Mayor Carlos A. Gimenez said in a statement Monday. • The return of Major League Baseball is at risk after the Houston Astros and Washington Nationals canceled their team workouts Monday, citing delays in receiving coronavirus test results. “We cannot have our players and staff work at risk,” Mike Rizzo, the Nationals’ GM said in a statement.
  • 07/06/2020

Abbott Deal, UnitedHealth Coverage Push Up Tandem Shares

  • Stock of San Diego-based medical device company hits one-year high Continue reading...
  • 07/06/2020

Coronavirus latest: Monday, July 6

  • The United States topped over 130,000 new cases of coronavirus over the 4th of July holiday weekend, with Florida and Texas breaking new daily case records. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
  • 07/06/2020

Becton Dickinson Cleared by FDA for 15-Minute Virus Test

  • Becton Dickinson said it was cleared by the FDA to market a 15-minute coronavirus diagnostic test and will begin shipping the test this week.
  • 07/06/2020

BD's stock gains on launch of rapid COVID-19 diagnostic test

  • Shares of Becton Dickinson & Co. gained 3.6% in premarket trading on Monday after the diagnostics company announced the launch of a point-of-care COVID-19 antigen test that can detect the coronavirus in 15 minutes. It's the third BD COVID-19 diagnostic test to receive emergency use authorization from the Food and Drug Administration during the pandemic. "This will be a game-changer for frontline health care workers and their patients to be able to access a quick diagnostic test for COVID-19, offering results in real-time at convenient locations like retail pharmacies, urgent care centers and doctors' offices," Dave Hickey, president of BD's integrated diagnostic solutions business, said in a news release. BD's stock is down 9.9% year-to-date, while the S&P; 500 has declined 3.1%.
  • 07/06/2020

Becton Dickinson's rapid antigen test for COVID-19 authorized by FDA, shares rise

  • Becton Dickinson shares rose $5.40, or 2.3%, to $250.61 in early trading. The authorization was based on a robust sample size of 226 specimens from sites across the United States, Evercore ISI analyst Vijay Kumar said in a research note. "We think the new antigen test will play a big role in the coming flu season as a rapid, rule out test," Kumar said.
  • 07/06/2020

U.S. regulator greenlights Becton Dickinson's rapid antigen test for COVID-19

  • The U.S. Food and Drug Administration has granted emergency use authorization (EUA) to Becton Dickinson and Co for a COVID-19 antigen test that can be administered at the point of care and produce results within 15 minutes, the company said on Monday. The FDA has touted the tests as an important tool for combating the pandemic because they can be produced quickly, at relatively low costs, and test patients in a variety of settings. Becton Dickinson's test can be used on its existing BD Veritor System platform, which is employed in about 25,000 healthcare facilities across the United States.
  • 07/06/2020

BD Launches Portable, Rapid Point-of-Care Antigen Test to Detect SARS-CoV-2 in 15 minutes, Dramatically Expanding Access to COVID-19 Testing

  • BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a rapid, point-of-care, SARS-CoV-2 diagnostic test for use with its broadly available BD Veritor™ Plus System. The launch of this new assay that delivers results in 15 minutes on an easy-to-use, highly portable instrument is critical for improving access to COVID-19 diagnostics because it enables real-time results and decision making while the patient is still onsite.
  • 07/06/2020

BD Announces Live Webcast Of Third Fiscal Quarter Earnings Conference Call

  • BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2020 earnings conference call on Thursday, August 6, 2020, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter's earnings earlier that morning.
  • 07/02/2020

Here’s Why Colliers Group (CIGI) Stock is an Attractive Pick for Investors

  • PenderFund Capital Management recently released its May 2020 Investor Letter, a copy of which you can download here. Pender is a growing, independent, value-based mutual fund company with the goal of creating value by generating superior risk-adjusted returns. You should check out PenderFund Capital Management's top 5 stock picks for investors to buy right now, […]
  • 06/19/2020

Why Is Becton Dickinson (BDX) Down 5.6% Since Last Earnings Report?

  • Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  • 06/06/2020

5 Stocks to Buy for an Uncertain 2020

  • With the market finding its way through tricky economic territory, investors will have to strike a careful balance between offensive and defensive moves. These five stocks will help you finesse your approach, with a blend of classic safety plays, companies that will shine as the economy recovers and those that poised to profit in a post-pandemic world. SEE ALSO: All 30 Dow Stocks Ranked: The Pros Weigh In
  • 06/04/2020
Unlock
BDXB Ratings Summary
BDXB Quant Ranking